Guest Columns

  1. 5 Questions To Ask Your CDMO: #4 – What’s Your Sweet Spot?
    12/11/2018

    Virtually every biotech or pharmaceutical company relies on contract development and manufacturing organizations (CDMOs) for R&D and manufacturing services or to access specialized technology to bring their drug candidates to the market. Identifying and selecting CDMOs is a lengthy and difficult process, and it is critically important to select the right partner.

  2. Cybersecurity Among Biggest Challenges For Pharma Firms Incorporating Digital Health Technologies
    12/7/2018

    This is the second of two articles, this part focuses on the importance of cybersecurity and software maintenance, how time scales and methods of execution differ from those in traditional pharma, how agile software development works, and how to avoid potential pitfalls.

  3. Biosimilar Coverage By The VA — What You Need To Know
    12/6/2018

    Merck’s recent announcement that its infliximab biosimilar, Renflexis, was awarded a U.S. Department of Veterans Affairs (VA) national contract has sparked curiosity about the potential influence this might have on biosimilar adoption and formulary preference in the rest of the market. Renflexis was determined to be the lowest-priced infliximab proposed under a competitive solicitation and, as such, was awarded preferred use as the only infliximab option covered on the VA National Formulary (VANF).

  4. What Do Sites Really Want From Sponsors And CROs? ACRP/Avoca Survey Explains
    12/6/2018

    The Association of Clinical Research Professionals (ACRP) and The Avoca Group surveyed nearly 300 clinical trial study site staff earlier this year to determine the most important factors for advancing quality in studies from their perspectives. A total of 151 respondents assessed sponsor organizations and 130 evaluated contract research organizations (CROs). Respondents were asked to comment on up to three companies they’d worked with during the previous 12 months.

  5. Cardiac Stem Cell Controversy — 3 Important Lessons Learned
    12/6/2018

    Heart problems have touched many of our lives, or the lives of those we care about. Heart attacks and heart failure are leading killers in the U.S.,1 with limited treatment options available today. Typically, a heart attack is followed by significant heart muscle cell death, leaving the organ in a weakened state and the patient at risk of cardiovascular dysfunction and eventual heart failure. This leads to many of the deaths attributed to cardiovascular disease.

  6. Data Integrity, Startups, & Cloud Storage: Don’t Let This Happen To You!
    12/5/2018

    Data integrity is of paramount importance to ensure patient health and safety and to improve shareholder value, particularly for virtual companies. Startups finding themselves in the throes of managing complex drug development programs realize they may face great risk if they do not begin with the end in mind and integrate data integrity practices early on.

  7. Digital Health Companies Chasing US, EU Markets Need To Move With The Regulatory Pendulum
    12/5/2018

    By addressing four areas of common requirement, medical device companies will be in a stronger position to secure authorization and maintain products on both the US and EU markets.

  8. What’s In A Name? Understanding Unmet Medical Need May Help Align Prioritization Strategies
    12/4/2018

    Unmet medical need (UMN) is not a new concept, but it is an increasingly important one. Regulators and payers are nudging the industry to steer R&D investments toward areas with higher unmet need and less crowded pipelines.

  9. Continued Process Verification And The Validation Of Informatics Systems For Pharmaceutical Processing
    12/3/2018

    This article, written by members of the BioPhorum Operations Group (BPOG) Continued Process Verification (CPV) Informatics team, summarizes their collective experience in validating the informatics components of their CPV programs, to shed light on common issues and provide recommendations and best practices.

  10. Dos And Don’ts Of Assessing Usage Risk
    12/3/2018

    Effectively conducting a uFMEA not only facilitates correct identification of existing usage risk, it aids in the generation of crucial design updates for risk reduction or elimination.